Research and experimental development on natural sciences and engineering
ONCOSYNE AS
Revenue 2024
NOK 4.4m
Operating profit
NOK −2.0m
Equity
NOK 10.8m
Incorporated
2020
Employees
6
Share capital
NOK 1.1m
Key figures · 2024
Current ratio
9.24
Equity ratio
90.0%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -45.2% | |
| Net margin (%%) | -39.3% | |
| Return on assets (%%) | -16.6% | |
| Likviditet | ||
| Current ratio | 9.24 | |
| Working capital | 9.9m | |
| Soliditet | ||
| Equity ratio (%%) | 90.0% | |
| Debt-to-equity ratio | 0.11 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.